Randomized, Double Blind, Placebo Controlled "First In-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers

Trial Profile

Randomized, Double Blind, Placebo Controlled "First In-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2015

At a glance

  • Drugs PBF 509 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Planned End Date changed to 31 Dec 2012, as reported in a Palobiofarma media release.
    • 01 Nov 2012 Status changed from not yet recruiting to recruiting, according to a Palobiofarma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top